Platinum‐based adjuvant chemotherapy for early‐stage epithelial ovarian cancer: single or combination chemotherapy?

Abstract

Combination therapy is administered more often than carboplatin; especially in those with younger age, better PS and nonmucinous histology. Recurrence and death rates were similar with both treatments. Well-designed trials are needed to identify the optimum chemotherapy regimen in this group.